117 related articles for article (PubMed ID: 25801700)
1. RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.
Sonnemann J; Grauel D; Blümel L; Hentschel J; Marx C; Blumrich A; Focke K; Becker S; Wittig S; Schinkel S; Krämer OH; Beck JF
Eur J Cancer; 2015 May; 51(7):841-51. PubMed ID: 25801700
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.
Sonnemann J; Palani CD; Wittig S; Becker S; Eichhorn F; Voigt A; Beck JF
Eur J Cancer; 2011 Jun; 47(9):1432-41. PubMed ID: 21334198
[TBL] [Abstract][Full Text] [Related]
3. Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity.
Sonnemann J; Kahl M; Siranjeevi PM; Blumrich A; Blümel L; Becker S; Wittig S; Winkler R; Krämer OH; Beck JF
J Cancer Res Clin Oncol; 2016 Jan; 142(1):17-26. PubMed ID: 26055805
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.
Sturm MJ; Henao-Restrepo JA; Becker S; Proquitté H; Beck JF; Sonnemann J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8605-8617. PubMed ID: 37097390
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells.
Kerschner-Morales SL; Kühne M; Becker S; Beck JF; Sonnemann J
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2871-2883. PubMed ID: 32770382
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.
Kravchenko JE; Ilyinskaya GV; Komarov PG; Agapova LS; Kochetkov DV; Strom E; Frolova EI; Kovriga I; Gudkov AV; Feinstein E; Chumakov PM
Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6302-7. PubMed ID: 18424558
[TBL] [Abstract][Full Text] [Related]
7. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.
Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H
Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240
[TBL] [Abstract][Full Text] [Related]
8. p53-dependent and p53-independent anticancer activity of a new indole derivative in human osteosarcoma cells.
Cappadone C; Stefanelli C; Malucelli E; Zini M; Onofrillo C; Locatelli A; Rambaldi M; Sargenti A; Merolle L; Farruggia G; Graziadio A; Montanaro L; Iotti S
Biochem Biophys Res Commun; 2015 Nov; 467(2):348-53. PubMed ID: 26433123
[TBL] [Abstract][Full Text] [Related]
9. The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line.
Marx C; Marx-Blümel L; Lindig N; Thierbach R; Hoelzer D; Becker S; Wittig S; Lehmann R; Slevogt H; Heinzel T; Wang ZQ; Beck JF; Sonnemann J
Invest New Drugs; 2018 Jun; 36(3):396-406. PubMed ID: 29150734
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
11. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
13. Response of Ewing tumor cells to forced and activated p53 expression.
Kovar H; Pospisilova S; Jug G; Printz D; Gadner H
Oncogene; 2003 May; 22(21):3193-204. PubMed ID: 12761489
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
15. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
[TBL] [Abstract][Full Text] [Related]
16. p21 (WAF1/Cip1/Sdi1/Pic1) mRNA is expressed in neuroblastoma cell lines but not in Ewing's sarcoma and primitive neuroectodermal tumor cell lines.
Maeda T; Nishimura N; Nakamura H; Sano K
Acta Paediatr Jpn; 1997 Oct; 39(5):590-4. PubMed ID: 9363658
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
18. Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells.
Kuroda K; Fukuda T; Okumura K; Yoneyama H; Isogai H; Savage PB; Isogai E
Anticancer Drugs; 2013 Sep; 24(8):826-34. PubMed ID: 23817390
[TBL] [Abstract][Full Text] [Related]
19. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
20. Effects of baicalein on proliferation, apoptosis, migration and invasion of Ewing's sarcoma cells.
Ye C; Yu X; Zeng J; Dai M; Zhang B
Int J Oncol; 2017 Dec; 51(6):1785-1792. PubMed ID: 29039470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
